{"brief_title": "Arimidex in McCune Albright Syndrome", "brief_summary": "The primary objective of this study is to evaluate the safety and efficacy of anastrozole 1 mg given once daily in subjects with McCune-Albright Syndrome.", "condition": "McCune-Albright Syndrome", "intervention_type": "Drug", "intervention_name": "Arimidex 1 mg", "description": "Arimidex (anastrozole) 1mg once daily by mouth", "arm_group_label": "1", "criteria": "Inclusion Criteria: - informed written consent of parent/legal guardian and subject assent (as needed by local requirements) - females less than or equal to 10 years of age - diagnosed with McCune-Albright Syndrome - have progressive precocious puberty Exclusion Criteria: Any one of the following is regarded as a criterion for exclusion from the study: - any prior treatment of MAS associated with progressive precocious puberty with a third generation aromatase inhibitor (anastrozole, letrozole, exemestane) in which no clinical response was seen - concomitant treatment of precocious puberty associated with MAS, with the exception of bisphosphonates for polyostotic fibrous dysplasia and LHRH analogues in the case of central precocious puberty - liver function tests at screening visit (AST, ALT) > or = 3x the upper limit of the reference range for age - known hypersensitivity to any component of study medication", "gender": "Female", "minimum_age": "N/A", "maximum_age": "10 Years", "healthy_volunteers": "No", "id": "NCT00055302.xml"}